Yes, but even late stage patients don't have too many options because clinical trials are usually designed to follow very specific algorithms of treatments and reject patients who don't exactly fit in. So there is actually a lot of friction in the current system, and the fact that clinical trials are typically expensive for companies to run just exacerbates things.